Haloperidol

Generic Name: Haloperidol

Brand Names: Haldol

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃ClFNO_₂

CAS Number: 52-86-8

Unique Ingredient Identifier: J6292F8L3D

Background: Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularl...

Indication: Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted ...

Associated Conditions: Aggression, Delirium, Gilles de la Tourette's Syndrome, Huntington's Disease (HD), Nausea and vomiting, Obsessive Compulsive Disorder (OCD), Psychosis, Schizophrenia, Severe Disruptive Behaviour Disorders, Severe Hyperactivity

Associated Therapies: -

Clinical Trials

Clozapine IM and Aggression in Schizophrenic Patients

Phase 3

Withdrawn

Conditions: Schizophrenia

First Posted Date: 2005-09-19

Last Posted Date: 2013-07-24

Lead Sponsor: Beersheva Mental Health Center

Registration Number: NCT00189995

Locations: 🇮🇱
Nes Ziona Medical Center, Nes Ziona, Israel
🇮🇱
Beersheva Mental Health Center, Beersheva, Israel

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia

Interventions: Drug: Clozapine
Drug: Haloperidol

First Posted Date: 2005-09-15

Last Posted Date: 2015-04-07

Lead Sponsor: Harvard Medical School (HMS and HSDM)

Target Recruit Count: 32

Registration Number: NCT00169091

Locations: 🇺🇸
Commonwealth Research Center, Jamaica Plain, Massachusetts, United States

Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Asenapine
Drug: Haloperidol

First Posted Date: 2005-09-12

Last Posted Date: 2022-02-08

Lead Sponsor: Organon and Co

Target Recruit Count: 187

Registration Number: NCT00156065

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Other: Placebo arm
Drug: Asenapine
Drug: Haloperidol

First Posted Date: 2005-09-12

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 460

Registration Number: NCT00156104

Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: placebo
Drug: haloperidol
Drug: olanzapine

First Posted Date: 2005-08-11

Last Posted Date: 2010-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 224

Registration Number: NCT00129220

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Phase 3

Terminated

Conditions: Nausea
Neoplasms

First Posted Date: 2005-07-29

Last Posted Date: 2012-01-19

Lead Sponsor: Alberta Health services

Target Recruit Count: 80

Registration Number: NCT00124930

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Study of Aripiprazole in Patients With Acute Bipolar Mania

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Aripiprazole
Drug: Haloperidol

First Posted Date: 2004-11-22

Last Posted Date: 2013-11-08

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 615

Registration Number: NCT00097266

Locations: 🇿🇦
Local Institution, Berea, Kwa Zuluu Natal, South Africa

The MIND Study: Modifying the INcidence of Delirium

Phase 2

Completed

Conditions: Delirium
Cognition Disorders

Interventions: Other: Placebo
Drug: Ziprasidone
Drug: Haloperidol

First Posted Date: 2004-11-17

Last Posted Date: 2016-01-29

Lead Sponsor: Vanderbilt University

Target Recruit Count: 102

Registration Number: NCT00096863

Locations: 🇺🇸
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Moses Cone, Greensboro, North Carolina, United States

and more 2 locations

5HT3 Antagonism and Auditory Gating in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

First Posted Date: 2001-07-05

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00018850

Locations: 🇺🇸
VAMC, Denver, Colorado, United States

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

Phase 4

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: Olanzapine
Drug: Haloperidol

First Posted Date: 2001-01-01

Last Posted Date: 2009-02-04

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 600

Registration Number: NCT00007774

Locations: 🇺🇸
VA Medical Center, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, United States
🇺🇸
VA Medical Center, Bay Pines, Bay Pines, Florida, United States

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy